Quality of life of children aged 8-12 years undergoing food allergy oral immunotherapy: Child and parent perspective.
desensitization
food allergy
maintenance dose
oral immunotherapy
quality of life
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
11
01
2020
revised:
13
03
2020
accepted:
25
03
2020
pubmed:
1
5
2020
medline:
15
5
2021
entrez:
1
5
2020
Statut:
ppublish
Résumé
Oral immunotherapy (OIT) for food allergy improves the quality of life (QOL) of children from parental perspective but little is known about the child perception. The Food Allergy Quality of Life Questionnaire-Child Form (FAQLQ-CF) was administered to children aged 8-12 years, and the FAQLQ-Parent Form (FAQLQ-PF) was administered to their parents at the start of OIT for milk, egg, peanut, sesame, or tree nuts, at the end of up-dosing, and after 6 months of follow-up. Food-allergic children not undergoing OIT served as controls. Children QOL scores were compared to their parents. The total FAQLQ-CF score of 103 children undergoing OIT improved significantly from start of OIT (median (IQR); 4.8, 3.8-5.7) to end of up-dosing (3.9, 3-5.2) (P < .001). A greater improvement was noted in the 56 children who reached a follow-up visit, from 5.0 (3.7-5.8) at OIT start to 3.1 (1.8-5.0) on follow-up, (P < .001). In contrast, FAQLQ-CF scores of control patients improved mildly and nonsignificantly between the two time points from 5.3 (4.3-5.7) to 4.8 (3.6-6.0), (P = .13). The improvement in the total FAQLQ-CF scores from OIT start to follow-up was significantly greater compared to the change in control patients during observation (P = .015). Parents reported better QOL scores compared to their children at all stages of OIT (start 4.0, 3.2-5, P = .004; end of up-dosing 2.9, 1.9-4.7, P = .04; follow-up 2.2, 1.6-3.6, P = .003). QOL of food-allergic children undergoing OIT improves significantly compared to controls. Parents perceive QOL to be better than the perception of the children.
Sections du résumé
BACKGROUND
Oral immunotherapy (OIT) for food allergy improves the quality of life (QOL) of children from parental perspective but little is known about the child perception.
METHODS
The Food Allergy Quality of Life Questionnaire-Child Form (FAQLQ-CF) was administered to children aged 8-12 years, and the FAQLQ-Parent Form (FAQLQ-PF) was administered to their parents at the start of OIT for milk, egg, peanut, sesame, or tree nuts, at the end of up-dosing, and after 6 months of follow-up. Food-allergic children not undergoing OIT served as controls. Children QOL scores were compared to their parents.
RESULTS
The total FAQLQ-CF score of 103 children undergoing OIT improved significantly from start of OIT (median (IQR); 4.8, 3.8-5.7) to end of up-dosing (3.9, 3-5.2) (P < .001). A greater improvement was noted in the 56 children who reached a follow-up visit, from 5.0 (3.7-5.8) at OIT start to 3.1 (1.8-5.0) on follow-up, (P < .001). In contrast, FAQLQ-CF scores of control patients improved mildly and nonsignificantly between the two time points from 5.3 (4.3-5.7) to 4.8 (3.6-6.0), (P = .13). The improvement in the total FAQLQ-CF scores from OIT start to follow-up was significantly greater compared to the change in control patients during observation (P = .015). Parents reported better QOL scores compared to their children at all stages of OIT (start 4.0, 3.2-5, P = .004; end of up-dosing 2.9, 1.9-4.7, P = .04; follow-up 2.2, 1.6-3.6, P = .003).
CONCLUSIONS
QOL of food-allergic children undergoing OIT improves significantly compared to controls. Parents perceive QOL to be better than the perception of the children.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2623-2632Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Sicherer SH, Sampson H. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141:41-58.
Tang MLK, Mullins RJ. Food allergy: is prevalence increasing? Intern Med J. 2017;47:256-261.
Nachshon L, Schwartz N, Elizur A, et al. The prevalence of food allergy in young Israeli adults. J Allergy Clin Immunol Pract. 2019;7:2782-2789.
Patel N, Herbert L, Green TD. The emotional, social, and financial burden of food allergies on children and their families. Allergy Asthma Proc. 2017;38:88-91.
Shaker MS, Schwartz J, Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29:497-502.
DunnGalvin A, Dubois AEJ, Flokstra-de Blok BMJ, Hourihane JO. The effects of food allergy on quality of life. Chem Immunol Allergy. 2015;101:235-252.
Bollinger ME, Dahlquist LM, Mudd K, Sonntag C, Dillinger L, McKenna K. The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol. 2006;96:415-421.
Feng C, Kim J-H. Beyond avoidance: the psychosocial impact of food allergies. Clin Rev Allergy Immunol. 2019;57:74-82.
Stensgaard A, Bindslev-Jensen C, Nielsen D, Munch M, DunnGalvin A. Quality of life in childhood, adolescence and adult food allergy: patient and parent perspectives. Clin Exp Allergy. 2017;47:530-539.
Östblom E, Egmar A-C, Gardulf A, Lilja G, Wickman M. The impact of food hypersensitivity reported in 9-year-old children by their parents on health-related quality of life. Allergy. 2008;63:211-218.
Allen CW, Bidarkar MS, vanNunen SA, Campbell DE. Factors impacting parental burden in food-allergic children. J Paediatr Child Health. 2015;51:696-698.
Hussey Freeland DM, Manohar M, Andorf S, Hobson BD, Zhang W, Nadeau KC. Oral immunotherapy for food allergy. Semmin Immunol. 2017;30:36-44.
Nachshon L, Goldberg MR, Katz Y, Levy MB, Elizur A. Long-term outcome of peanut oral immunotherapy-Real-life experience. Pediatr Allergy Immunol. 2018;29:519-526.
Kauppila TK, Paassilta M, Kukkonen AK, Kuitunen M, Pelkonen AS, Makela MJ. Outcome of oral immunotherapy for persistent cow’s milk allergy from 11 years of experience in Finland. Pediatr Allergy Immunol. 2019;30:356-362.
Mota I, Piedade S, Gaspar Â, et al. Cow’s milk oral immunotherapy in real life: 8-year long-term follow-up study. Asia Pac Allergy. 2018;8:e28.
Gernez Y, Nowak-Węgrzyn A. Immunotherapy for food allergy: are we there yet? J Allergy Clin Immunol Pract. 2017;5:250-272.
Jones SM, Burks AW, Keet C, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137:1117-1127.e10.
Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383:1297-1304.
Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in cow’s milk allergic patients: course and long-term outcome according to asthma status. Ann Allergy Asthma Immunol. 2015;114:240-244.e1.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;5(73):799-815.
Hsiao K-C, Ponsonby A-L, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Heal. 2017;1:97-105.
Nachshon L, Goldberg MR, Levy MB, et al. Efficacy and safety of sesame oral immunotherapy-A Real-World, Single-Center Study. J Allergy Clin Immunol Pract. 2019;7:2775-2781.
Elizur A, Appel MY, Nachshon L, et al. Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER): a single-centre, prospective cohort study. Lancet Child Adolesc Heal. 2019;3:312-321.
LeBovidge JS, Haskell S, Olney EK, et al. The psychological impact of oral immunotherapy for children with food allergy: Perceived benefits and treatment burden. Clin Pract Pediatr Psychol. 2014;2:13-26.
Wood RA. Food allergen immunotherapy: Current status and prospects for the future. J Allergy Clin Immunol. 2016;137:973-982.
Vazquez-Ortiz M, Turner PJ. Improving the safety of oral immunotherapy for food allergy. Pediatr Allergy Immunol. 2016;27:117-125.
Levy MB, Elizur A, Goldberg MR, Nachshon L, Katz Y. Clinical predictors for favorable outcomes in an oral immunotherapy program for IgE-mediated cow’s milk allergy. Ann Allergy, Asthma Immunol. 2014;112:58-63.e1.
Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;1(393):2222-2232.
Dunn Galvin A, McMahon S, Ponsonby A-L, Hsiao K-C, Tang MLK. PPOIT study team. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy. 2018;73:560-568.
Otani IM, Bégin P, Kearney C, et al. Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects. Allergy Asthma Clin Immunol. 2014;10:25.
Carraro S, Frigo AC, Perin M, et al. Impact of oral immunotherapy on quality of life in children with cow milk allergy: a pilot study. Int J Immunopathol Pharmacol. 2012;25:793-798.
Vazquez-Ortiz M, Alvaro M, Piquer M, et al. Impact of oral immunotherapy on quality of life in egg-allergic children. Pediatr Allergy Immunol. 2015;26:291-294.
Epstein Rigbi N, Katz Y, Goldberg MR, Levy MB, Nachshon L, Elizur A. Patient quality of life following induction of oral immunotherapy for food allergy. Pediatr Allergy Immunol. 2016;27:263-268.
Rigbi NE, Goldberg MR, Levy MB, Nachshon L, Golobov K, Elizur A. Changes in patient quality of life during oral immunotherapy for food allergy. Allergy. 2017;72:1883-1890.
Epstein-Rigbi N, Goldberg MR, Levy MB, Nachshon L, Elizur A. Quality of life of food-allergic patients before, during, and after oral immunotherapy. J Allergy Clin Immunol Pract. 2019;7:429-436.
Wassenberg J, Cochard M-M, DunnGalvin A, et al. Parent perceived quality of life is age-dependent in children with food allergy. Pediatr Allergy Immunol. 2012;23:412-419.
van der Velde JL, Flokstra-de Blok BMJ, Dunngalvin A, Hourihane JO, Duiverman EJ, Dubois AEJ. Parents report better health-related quality of life for their food-allergic children than children themselves. Clin Exp Allergy. 2011;41:1431-1439.
Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol. 2012;109:348-352.e2.
Blumchen K, Trendelenburg V, Ahrens F, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J allergy Clin Immunol Pract. 2019;7:479-491.e10.
Reier-Nilsen T, Carlsen KCL, Michelsen MM, et al. Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial. Pediatr Allergy Immunol. 2019;30:638-645.
Nachshon L, Goldberg MR, Elizur A, Levy MB, Schwartz N, Katz Y. A Web site-based reporting system for monitoring home treatment during oral immunotherapy for food allergy. Ann Allergy Asthma Immunol. 2015;114:510-515.
Flokstra-de Blok BMJ, DunnGalvin A, Vlieg-Boerstra BJ, et al. Development and validation of a self-administered food allergy quality of life questionnaire for children clinical and experimental allergy. Clin Exp Allergy. 2008;39:127-137.
van der Velde JL, Flokstra-de Blok BMJ, Vlieg-Boerstra BJ, et al. Development, validity and reliability of the food allergy independent measure (FAIM). Allergy. 2010;65:630-635.
WHO. Process of translation and adaptation of instruments. https://www.who.int/substance_abuse/research_tools/translation/en/. Accessed June 30, 2014.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-415.
Greenhawt M, Marsh R, Gilbert H, Sicherer S, DunnGalvin A, Matlock D. Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies. Ann Allergy Asthma Immunol. 2017;121:575-579.
Dunn Galvin A, Hourihane JO. Psychosocial mediators of change and patient selection factors in oral immunotherapy trials. Clin Rev Allergy Immunol. 2018;55:217-236.
Elizur A, Appel MY, Goldberg MR, et al. Clinical and laboratory 2-year outcome of oral immunotherapy in patients with cow’s milk allergy. Allergy. 2016;71:275-278.
Kansen HM, Le T-M, Meijer Y, et al. The impact of oral food challenges for food allergy on quality of life: a systematic review. Pediatr Allergy Immunol. 2018;29:527-537.
Dantzer JA, Wood RA. The impact of tree nut oral food challenges on quality of life and acute reactions in nut allergic patients. J Allergy Clin Immunol Pract. 2019;7:698-700.e1.
Waters E, Doyle J, Wolfe R, Wright M, Wake M, Salmon L. Influence of parental gender and self-reported health and illness on parent-reported child health. Pediatrics 2000;106:1422-1428.